Product name | SR9009 |
CAS | 1379686-30-2 |
Product Categories | SARMs(Selective androgen receptor modulator) |
Storage temp. | Refrigerator |
Appearance | White Powders |
Purity | 99% |
Usage | It is a potent and tissue-selective androgen receptor modulator (SARM). |
Description
SR9009 also known as Stenabolic,is a synthetic Rev-Erb ligand and PPAR alpha modifier drug,which is taken orally.This is a very unique compound. By stimulating the Rev-Erb protein, SR9009 has the ability to greatly influence a lot of regulatory mechanisms in the human body.it can affect the circadian rhythms, lipid and glucose metabolism, fat-storing cells, as well as macrophages. SR9009 will allow the user to lose fat and drastically increase endurance, both of which are very desirable effects for an athlete.
By binding and activating the Rev-Erb protein, Stenabolic triggers a very wide range of processes in the body. The most prominent being the increase of mitochondria count in the muscles and an enhanced metabolism.As a consequence of the increased number of mitochondria in the muscles, the user will notice a drastic improvement in endurance and muscle strength. In fact, the mice used in studies could run 50% more when they were administered with SR9009, both in terms of distance and time. This is possible due to the fact that these mitochondria are precisely the ones generating energy in the body. Besides, thanks to the increase in number of macrophages, defective mitochondria are removed from the muscles and replaced with new ones.
Furthermore, the change in metabolic rates increases energy expenditure by 5% even when the user is resting; hence, SR burns excess calories and doesn't allow them to convert into fat. This, coupled with enhanced metabolism of glucose, helps effectively burn fat, which makes the body act is if it were in a constant state of exercise.
Application
SR9009 affects the primary biological clock, which coordinates the rhythm of the body’s activity with the 24-hour phase of day and night.
Recent research show that activation of Rev-erbα with SR9009 resulted to enhanced metabolic activity in skeletal muscle tissue in both culture and in mice. The authors of this new research propose that Rev-erbα affects muscle cells by stimulating both the formation of new mitochondria (more known as the “power plants” of the cell) and the authorization of those mitochondria that are flawed.
If the effects of SR9009 on mice can securely be duplicated for people, the new drug may provide new treatments for obesity and its companions, metabolic syndrome and diabetes. Another area in which SR9009 or a similar drug may present significant benefit is to balance the loss of overall muscle conditioning which transpires as a side effect of reduced activity due to sickness or old age.